Both companies will jointly execute development and scale-up of multiple strategic APIs, including late-stage NCE-1 opportunities
India has deep strengths in reverse engineering and API development, while Russia has strong capabilities in certain vaccines, biologicals, and niche therapeutic segments. Collaboration can significantly shorten R&D timelines
Expanding US operations to address the increased demand for API development and manufacturing
The collaboration combines the extensive CMC expertise of Sai Life Sciences in API development, Agility Life Sciences in formulation development, and Centrix Pharma Solutions in drug product development and clinical manufacturing
It offers clear environmental benefits, lower emissions, reduced hazardous material use, and alignment with circular economy goals
Newly commissioned MCC in Jhagadia and Dahej and CCS project expansions will unlock an additional 8,800 MTPA, fuelling year-over-year revenue gains of 20%-30% in excipients
Centre for Continuous Manufacturing and Advanced Crystallisation (CMAC) aims to accelerate the digital transformation of CMC development and manufacturing approaches
The company is committed to revolutionizing API development by advancing synthesis and analytical processes that enhance quality and impact lives
Expanded capacity in Nansha, China will support mid-scale manufacturing to ensure a smooth transition between early-phase and large-scale commercial production
The focus of the companies in this partnership is to synergise capabilities, leverage research and bring innovative products in specific therapeutic areas
Subscribe To Our Newsletter & Stay Updated
